Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in Morristown, New Jersey.
| Revenue (TTM) | $7.14M |
| Gross Profit (TTM) | $-84.58M |
| EBITDA | $-114.32M |
| Operating Margin | -1601.00% |
| Return on Equity | -21.80% |
| Return on Assets | -64.70% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $2.89 |
| Price-to-Book | 1.91 |
| Price-to-Sales (TTM) | 31.08 |
| EV/Revenue | 8.32 |
| EV/EBITDA | -0.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $49.45M |
| Float | $18.15M |
| % Insiders | 13.75% |
| % Institutions | 72.47% |
Volatility is currently expanding